Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: SusieQ1065 who wrote (12284)	8/23/2001 9:03:10 PM
From: RKHIII	Read Replies (1) \| Respond to of 208838

I follow MANU and it was refreshing to see it green all day. One anal-yst had said it needed to close too many deals to be able to make numbers this quarter (it met them last report on 6/21). Too soon to tell, but it could finally be turning up. I'm watching the GSO.X closely.

To: SusieQ1065 who wrote (12284)	8/23/2001 9:27:34 PM
From: 2MAR$	Respond to of 208838

More woe for PDII , see's lowering 2002 earnings by $1.50 a share and lower 2002 revenue by $225 million to $235 million. ( big ouch ) Pro Detailing Outlook -2: Street Saw '01 Net $2.24/Shr UPPER SADDLE RIVER, N.J. (Dow Jones)--Professional Detailing Inc. (PDII) expects a "severe impact" on revenue and earnings if a generic Ceftin antibiotic tablet is launched. In a press release Thursday, the drug sales and marketing company said the immediate launch of a generic version of Ceftin would reduce 2001 earnings by 80 cents to 90 cents a share and lower 2001 revenue by $50 million to $60 million. Professional Detailing said the launch would cut 2002 earnings by $1.50 a share and lower 2002 revenue by $225 million to $235 million. Thomson Financial/First Call analyst surveys had predicted the company would earn $2.24 a share on revenue of $655.5 million in 2001. On Monday, a U.S. appeals court in Washington overturned an order from a New Jersey District Court that prevented Indian drug maker Ranbaxy Laboratories Ltd. (P.RLB) from selling a generic version of GlaxoSmithKline PLC's (GSK) Ceftin product. The case was remanded back to the district court. Professional Detailing's LifeCycle Ventures Inc. unit is the exclusive marketer for Ceftin. (MORE) DOW JONES NEWS 08-23-01 More complete article here and live CC for tomorrow at 9am: biz.yahoo.com